BridgeBio Pharma (BBIO) Short Interest Ratio & Short Volume → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free BBIO Stock Alerts $30.09 -0.95 (-3.06%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability BridgeBio Pharma Short Interest DataCurrent Short Volume16,230,000 sharesPrevious Short Volume15,070,000 sharesChange Vs. Previous Month+7.70%Dollar Volume Sold Short$415.81 millionShort Interest Ratio / Days to Cover9.7Last Record DateApril 30, 2024Outstanding Shares187,130,000 sharesFloat Size140,850,000 sharesShort Percent of Float11.52%Today's Trading Volume2,247,140 sharesAverage Trading Volume1,477,570 sharesToday's Volume Vs. Average152% Short Selling BridgeBio Pharma ? Sign up to receive the latest short interest report for BridgeBio Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatBBIO Short Interest Over TimeBBIO Days to Cover Over TimeBBIO Percentage of Float Shorted Over Time Ad Porter & CompanyGuard Against the Coming Financial UpheavalAmerica’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late.You can stream it for free right here. BridgeBio Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202416,230,000 shares $415.81 million +7.7%11.5%9.7 $25.62 4/15/202415,070,000 shares $388.35 million +5.5%10.9%8.9 $25.77 3/31/202414,280,000 shares $441.54 million +6.5%10.3%8.3 $30.92 3/15/202413,410,000 shares $369.58 million -1.7%9.8%7.3 $27.56 2/29/202413,640,000 shares $465.81 million -2.6%10.0%7.1 $34.15 2/15/202414,000,000 shares $549.22 million -1.5%10.8%7.9 $39.23 Get the Latest News and Ratings for BBIO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter. 1/31/202414,210,000 shares $487.26 million -11.9%11.1%8.3 $34.29 1/15/202416,120,000 shares $623.84 million -5.6%12.6%9.7 $38.70 12/31/202317,080,000 shares $689.52 million -0.1%13.3%11 $40.37 12/15/202317,090,000 shares $672.83 million +7.1%13.3%11.4 $39.37 11/30/202315,960,000 shares $458.21 million -2.0%12.8%11.2 $28.71 11/15/202316,280,000 shares $480.59 million +1.9%13.0%10.8 $29.52 10/31/202315,970,000 shares $415.86 million -0.6%12.7%9.9 $26.04 10/15/202316,060,000 shares $418.84 million +4.8%13.7%9 $26.08 9/30/202315,320,000 shares $403.99 million -4.1%13.1%5.1 $26.37 9/15/202315,980,000 shares $465.50 million +4.2%13.6%5.2 $29.13 8/31/202315,330,000 shares $458.52 million -2.1%13.1%4.9 $29.91 8/15/202315,660,000 shares $477.00 million +8.5%13.4%5.1 $30.46 7/31/202314,430,000 shares $505.19 million -2.6%12.3%4.7 $35.01 7/15/202314,820,000 shares $270.02 million -0.6%12.8%5 $18.22 6/30/202314,910,000 shares $256.45 million +13.2%12.8%8.1 $17.20 6/15/202313,170,000 shares $204.40 million -2.5%11.3%6 $15.52 5/31/202313,510,000 shares $185.36 million +1.7%11.7%5.9 $13.72 5/15/202313,290,000 shares $197.22 million -6.4%11.5%4.2 $14.84 4/30/202314,200,000 shares $206.18 million -4.6%12.2%4.4 $14.52 4/15/202314,890,000 shares $219.48 million -1.8%12.8%4.7 $14.74 3/31/202315,160,000 shares $251.35 million -13.5%13.4%4.9 $16.58 3/15/202317,520,000 shares $249.66 million +4.6%15.5%6.3 $14.25 2/28/202316,750,000 shares $191.29 million +2.5%15.7%7.3 $11.42 2/15/202316,350,000 shares $199.47 million -12.3%15.3%11.7 $12.20 1/31/202318,650,000 shares $173.07 million +1.3%17.5%14.1 $9.28 1/15/202318,410,000 shares $161.09 million -3.1%17.3%14.7 $8.75 12/30/202219,000,000 shares $144.78 million -1.1%17.9%14.7 $7.62 12/15/202219,210,000 shares $171.16 million -4.5%18.1%14.8 $8.91 11/30/202220,110,000 shares $188.43 million -3.6%18.9%13.3 $9.37 11/15/202220,860,000 shares $217.99 million -6.5%19.7%13 $10.45 10/31/202222,310,000 shares $232.69 million -3.5%21.1%13.4 $10.43 10/15/202223,120,000 shares $228.43 million +0.6%22.0%11.2 $9.88 9/30/202222,980,000 shares $228.42 million -1.2%21.9%11 $9.94 9/15/202223,250,000 shares $277.61 million +0.6%22.2%10.6 $11.94He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (Ad)For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market.Click for his six specific AI stock in the crosshairs BBIO Short Interest - Frequently Asked Questions What is BridgeBio Pharma's current short interest? Short interest is the volume of BridgeBio Pharma shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 16,230,000 shares of BBIO short. 11.52% of BridgeBio Pharma's shares are currently sold short. Learn More on BridgeBio Pharma's current short interest. What is a good short interest ratio for BridgeBio Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BBIO shares currently have a short interest ratio of 10.0. Learn More on BridgeBio Pharma's short interest ratio. Which institutional investors are shorting BridgeBio Pharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of BridgeBio Pharma: Walleye Trading LLC, Jane Street Group LLC, PEAK6 Investments LLC, HAP Trading LLC, Concourse Financial Group Securities Inc., and Portman Square Capital LLP. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for BridgeBio Pharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.52% of BridgeBio Pharma's floating shares are currently sold short. Is BridgeBio Pharma's short interest increasing or decreasing? BridgeBio Pharma saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 16,230,000 shares, an increase of 7.7% from the previous total of 15,070,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is BridgeBio Pharma's float size? BridgeBio Pharma currently has issued a total of 187,130,000 shares. Some of BridgeBio Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. BridgeBio Pharma currently has a public float of 140,850,000 shares. How does BridgeBio Pharma's short interest compare to its competitors? 11.52% of BridgeBio Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to BridgeBio Pharma: Organon & Co. (4.71%), Ionis Pharmaceuticals, Inc. (6.53%), Apellis Pharmaceuticals, Inc. (10.21%), Cytokinetics, Incorporated (13.51%), Madrigal Pharmaceuticals, Inc. (18.67%), Alpine Immune Sciences, Inc. (5.67%), Blueprint Medicines Co. (7.25%), Nuvalent, Inc. (20.08%), Alkermes plc (7.62%), Perrigo Company plc (2.54%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short BridgeBio Pharma stock? Short selling BBIO is an investing strategy that aims to generate trading profit from BridgeBio Pharma as its price is falling. BBIO shares are trading down $0.95 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against BridgeBio Pharma? A short squeeze for BridgeBio Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BBIO, which in turn drives the price of the stock up even further. How often is BridgeBio Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BBIO, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: OGN Short Squeeze IONS Short Squeeze APLS Short Squeeze CYTK Short Squeeze MDGL Short Squeeze ALPN Short Squeeze BPMC Short Squeeze NUVL Short Squeeze ALKS Short Squeeze PRGO Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BBIO) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaUrgent Nvidia WarningAltimetryThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubMissed NVDA? Buy this AI stock NOWChaikin Analytics